Showing results (51-60 of 126) with videos related to
Sort By:
Pageof 13
Journal of the National Cancer Institute|June 21, 2019
A Review of Perspectives on the Use of Randomization in Phase II Oncology TrialsMichael J Grayling, Munyaradzi Dimairo, Adrian P Mander, et al.Biometrics|October 22, 2019
Bayesian design of biosimilars clinical programs involving multiple therapeutic indicationsMatthew A Psioda, Kuolung Hu, Yang Zhang, et al.Medical Care|July 6, 2021
Methodological Challenges and Statistical Approaches in the COMprehensive Post-Acute Stroke Services StudyMatthew A Psioda, Sara B Jones, James G Xenakis, et al.Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.Statistics in Medicine|November 1, 2022
The scale transformed power prior for use with historical data from a different outcome modelEthan M Alt, Brady Nifong, Xinxin Chen, et al.Biometrics|March 27, 2024
Case weighted power priors for hybrid control analyses with time-to-event dataEvan Kwiatkowski, Jiawen Zhu, Xiao Li, et al.Journal of Biopharmaceutical Statistics|April 19, 2024
Bayesian design of clinical trials using the scale transformed power priorXinxin Chen, Brady Nifong, Ethan M Alt, et al.Biostatistics (Oxford, England)|May 13, 2021
Bayesian adaptive design for concurrent trials involving biologically related diseasesMatthew A Psioda, H Amy Xia, Xun Jiang, et al.JCO Precision Oncology|January 5, 2024
Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future ProspectsZhulin Yin, Adrian P Mander, Johann S de Bono, et al.Pharmaceutical Statistics|January 11, 2012
Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesisAdrian P Mander, James M S Wason, Michael J Sweeting, et al.Pageof 13